Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Medicine, Oncology,
tumor mutational burden   immune checkpoint inhibition   metastatic melanoma   real-world study   biomarkers   efficacy prediction   BRAF status  

Study on Real-world Outcomes of First-line Immune Checkpoint Inhibitor Therapy in Metastatic Melanoma Predicted by Tumor Mutational Burden The treatment of metastatic melanoma has significantly benefited from immune checkpoint inhibitors (ICIs) in recent years. However, despite the remarkable improvement in survival rates among melanoma patients, t...

Efficacy-Effectiveness Analysis on Survival in a Population-Based Real-World Study of BRAF-Mutated Metastatic Colorectal Cancer Patients Treated with Encorafenib-Cetuximab

Medicine, Basic Medical Sciences, Gastroenterology, Oncology, Life Sciences, Genetics,
BRAF mutation   metastatic colorectal cancer   Encorafenib   Cetuximab   real-world study   survival rate   efficacy  

Efficacy-Effectiveness Analysis of Encorafenib-Cetuximab Treatment in Patients with Oncogene-Mutated Metastatic Colorectal Cancer: A Cohort Study Research Background With the advancement of personalized medicine, targeted therapy has become an important means to treat various cancers. In metastatic colorectal cancer (mCRC), the combination of encor...